Italy’s rational use of medicines Posted 08/04/2011
Italy was studied in detail in a report produced by the Gesundheit Österreich GmbH / Österreichisches Bundesinstitut für Gesundheitswesen (GÖG/ÖBIG – Austrian Health Institute). The report surveyed measures for promoting the rational use of medicines in the 27 EU member states.
Since 2000, the Italian Medicines Agency (Agenzia Italiana del Farmaco, AIFA) has been operating a ‘National Observatory on the Use of Medicines’ (Osservatorio nazionale sull’impiego dei medicinali, OSMED). OSMED monitors and analyses pharmaceutical consumption, e.g. impact of policy measures and comparison to other countries, on a monthly basis. Additionally, yearly reports on pharmaceutical consumption and expenditure are published. At regular intervals, AIFA runs information campaigns targeted at the general public, e.g. on rational use of antibiotics and promoting generics. International non-proprietary name prescribing is indicative for doctors and generic substitution is allowed, but not obligatory, for pharmacists in Italy. Italy has launched a project to trace all medicines brought on to the Italian market, Progetto Tracciabilità del Farmaco, which implied extensive preparatory work (legal framework, IT tools). Acknowledgement This article is published with permission of the Gesundheit Österreich GmbH (GÖG)/Austrian Health Institute. We gratefully acknowledge the support from Dr Sabine Vogler of Gesundheit Österreich GmbH / Österreichisches Bundesinstitut für Gesundheitswesen (GÖG/ÖBIG – Austrian Health Institute) to GaBI Online. Related articles The EU and rational use of medicines Survey on rational use of medicines in 27 EU Members States The Netherlands and rational use of medicines France’s rational use of medicines Rational use of medicines in Denmark Promoting rational use of medicines in Europe Germany’s rational use of medicines Reference Vogler S, Schmickl B. Rational use of medicines in Europe. Gesundheit Österreich GmbH / Österreichisches Bundesinstitut für Gesundheitswesen (GÖG/ÖBIG). February 2010.
Comments (0)
Generics News Research General
- Sanofi fined for discouraging generic clopidogr...Generics/News | Posted 17/05/2013
- FDA rejects Endo petition to stop Opana ER gene...Generics/News | Posted 17/05/2013
- The biggest drug patent losses for 2013Generics/General | Posted 17/05/2013
- Innovation in the generics industryGenerics/Research | Posted 10/05/2013
Biosimilars News Research General
- Agila Biotech and Pfenex make biosimilars dealBiosimilars/News | Posted 17/05/2013
- Sanofi starts biosimilar insulin trialsBiosimilars/News | Posted 10/05/2013
- Intas launches rituximab ‘similar biologic’ in...Biosimilars/News | Posted 10/05/2013
- Biosimilars approved in EuropeBiosimilars/General | Posted 08/07/2011




